ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO940

Antibodies Response in CKD Patients Vaccinated With CoronaVac

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Minczuk, Catarina, Faculdade de Medicina do ABC, Santo Andre, SP, Brazil
  • Fonseca, Fernando Luiz affonso, Faculdade de Medicina do ABC, Santo Andre, SP, Brazil
  • Mauad, Vitor Augusto Queiroz, Faculdade de Medicina do ABC, Santo Andre, SP, Brazil
  • Bacci, Marcelo Rodrigues, Faculdade de Medicina do ABC, Santo Andre, SP, Brazil
Background

Chronic Kidney Disease (CKD) has emerged as one of the major risk factors to a worse outcome in COVID19 (C19) patients. Vaccination became the main prevention policy against virus spread among individuals, apart from other measures, like using face masks and social distancing; however, CKD patients are a sensitive population excluded from many trials when eGFR are below 30 mL/min. C19 pandemic as never before, became possible vaccine development in a record time. CoronaVac, a live inactivated virus vaccine, was the main immunizing agent used in Brazil in the first wave of vaccination. Apart its safety and efficacy, there was no specific dose and regimen to immunosuppressed patients and advanced CKD population. The aim of this study was evaluate the SarsCov2 antibodies response after the full dose regimen of CoronaVac immunizing agent in CKD patients.

Methods

It is a cross sectional study conducted in Brazil during C19 second wave. Patients with stage 4 and 5 CKD were included with matched controls. Patients that received a full dosage regimen of CoronaVac, 2 shots of 0.5 mL (600 units of inactivated virus) with a 4 week interval were included. Total Sars-Cov2 antibodies and Spike antibodies were dosed after 12 weeks of the 2 dose CoronaVac regimen received. Siemens ADVIA Centaur® essays were used to determine antibodies levels and a cut off superior to 0.05 U/mL was considered positive. Descriptive analysis were made to show data with their central tendency characteristics. Qualitative data were described with their proportions and to non-normality inference, Mann-Whitney was used. The alpha level accepted was 5%.

Results

The study included 41 individuals in total: 19 patients with stage 4 and 5 CKD and 21 matched controls without renal disease. The mean age in the CKD group was 71,68 years (±7,79) and 72,95 years (±9,86) in control group. Male and female individuals were equal among groups. Total SarsCov2 antibodies levels were 4,32 U/mL (±4,16) in CKD group and 6,21 U/mL (±4,51) in controls with no statistical significance (p=0.46). Spike antibodies levels were 10,47 U/mL (±32,41) in CKD group and 10,35 U/mL (±28,34) in controls with a p=0.09 between groups using Mann-Whitney non parametric test.

Conclusion

In conclusion, CKD patients developed adequate levels of antibodies against C19 with CoronaVac full dosage regimen in Brazil after a 3 month period.